CureVac N.V. $450 million public offering
We advised CureVac on the equity offering

Davis Polk advised CureVac N.V. on its $450 million public offering of 5,000,000 of its common shares. The common shares are listed on the Nasdaq Global Market under the symbol “CVAC.”

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing and optimizing this versatile molecule for medical purposes. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt, Germany and Boston, Massachusetts.              

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay and associates Gil Savir and Yushen Liu. The tax team included partner Patrick E. Sigmon and associate Tomislava Dragicevic. The intellectual property and technology transactions team included partner David R. Bauer and associate Hilary Smith. The executive compensation team included partner Kyoko Takahashi Lin and associate Melissa Esposito. All members of the Davis Polk team are based in the New York office.